Merck & Co., Inc. vs Super Micro Computer Inc — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Super Micro Computer Inc trades at $38.92 (market cap $26.45B). The key difference: Merck & Co., Inc. is far larger — about 13.8× Super Micro Computer Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals.
| MRK | SMCI | |
|---|---|---|
Market Cap | $366.28B | $26.45B |
Sector | Health | Technology |
52-Week High | $156.43 | $58.68 |
52-Week Low | $77.60 | $20.53 |
Enterprise Value | $413.04B | $31.92B |
Dividend Yield | 2.29% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Super Micro Computer (SMCI) trades at $40.26, up 1.69% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 12.35 and ROE of 26.53%, supported by AI-driven revenue growth and a record backlog. Recent news highlights strong AI infrastructure demand and insider selling of $7.7 million in shares.
Outlook remains positive given AI server demand and improving margins, but risks include cash flow volatility and competitive pressures. Analysts are mixed with a $40.57 consensus target, suggesting limited near-term upside from current levels amid execution and market sentiment risks.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →